Navigation Links
Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
Date:11/15/2013

Arnhem, The Netherlands - An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

"Quantitative models predicting the risk of acute (and late) genito-urinary (GU) toxicity in patients treated with high dose radiotherapy for prostate cancer are lacking. This work represents one of the first attempts to provide radiation oncologists with quantitative tools to reliably predict the risk of moderate-severe acute GU effects based on both clinical and dosimetric individual parameters," said Dr. Cesare Cozzarini of the San Raffaele Scientific Institute, Dept. of Radiation Oncology in Milan, Italy.

Cozzarini presented the findings at the 5th European Multidisciplinary Meeting on Urological Cancers (EMUC) held in Marseille. A prospective cohort study (DUE-01) which started in April 2010, Cozzarini and colleagues aimed to develop predictive models of genito-urinary (GU) toxicity and erectile dysfunction after high dose radiotherapy (RT) for prostate cancer.

Patients treated with conventional (1.8-2Gy/fr, CONV) or moderate hypo-fractionation (2.5-2.7Gy/fr HYPO) were included.

In their ad-interim analysis, the investigators also intended to find a link between pollakiuria (POLL), dysuria (DYS) and nicturia (NICT) as measured by IPSS at RT end and clinical/dosimetric risk factors.

IPSS questionnaire at the start and at the end of RT were prospectively collected by the researchers and planning data were recovered and analyzed with a dedicated program (Vodca, MSS GmbH, Zurich), including absolute (cc/cm2) and % bladder dose-volume/surface (DVH/DSH) parameters referred to both the whole treatment and to the weekly delivered dose (DVHw/DSHw).

In the study, relevant clinical factors were also prospectively collected including T stage, concomitant morbidities and drugs, use of hormonal therapy (HT), previous surgery, smoking, age, BMI and prostate volume. In IPSS, each item ranges from 0 to 5 with increasing score which indicates increasing toxicity severity: for each question, a score≥4 at the end of the therapy was considered as the end point.

At the time of the analysis (January 2013), 339 patients have been enrolled by nine institutes. Clinical data of 212/339 patients were available (93 CONV and 119 HYPO). Of 172/212 patients both baseline and end-RT IPSS were collected. For 179/212 patients also DVH/DSH were available. Questions POLL, DYS and NICT (respectively 2, 3 and 7) showed the larger increase of the fraction of patients with scores ≥4 between basal and end questionnaire; consequently, the analysis focused on these symptoms.

The number of patients with scores≥4 increased from 8 to 30 for POLL, from 5 to 20 for DYS and from 12 to 34 for NICT. At MVA (overall p<0.0001), the main independent predictors of acute POLL were: Smoking (OR:2.74, p=0.04) and S8.5w (OR:1.01, p=0.10); AUC=0.66. The model was confirmed also after the exclusion of patients with baseline IPSS-POLL ≥4 (AUC=0.69).

"This study (DUE01) is aimed at prospectively collecting an enormous number of patient-reported information concerning GU toxicity (and erectile dysfunction as well) before, during and at the end of radiotherapy and for a period of five years after its completion," said Cozzarini.

"The study therefore has a high probability of helping to develop highly reliable models for the prediction of acute and late GU toxicity and erectile dysfunction and their impact on quality of life," he added.

"As a consequence, the final results of this investigation should have a significant impact on the evolution of radiotherapy of prostate cancer in the next five to 10 years leading to a significant reduction of GU toxicity and sexual dysfunction deriving from a more refined "tailoring" of the radiation therapy," according to Cozzarini.


'/>"/>

Contact: Evgenia Starkova
e.starkova@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Flavor Your Life Shares How to Prepare an Italian Style Orecchiette Pasta with Olive Oil
2. Flavor Your Life Shares 3 Easy Recipes that Use Italian Olive Oil to Enhance Meals
3. Mesothelioma News Update: Resource4thePeople Applauds Italian Court for Sentencing Swiss Millionaire in Asbestos Scandal
4. Springer partners with the Italian Society of Gerontology and Geriatrics
5. First Narconon Cannabis Abuse Prevention Guide Takes Aim at Drug Abuse Statistics for Italian Youth
6. Springer to collaborate with the Italian Society for the Study of Eating Disorders
7. Flavor Your Life Highlights the Importance of Taste in Italian Olive Oil
8. Nationally Renowned Health Expert Debuts Book "Sex and Spaghetti Sauce: My Italian Mother’s Recipe for Getting Healthy and Getting Busy in Your 50s and Beyond"
9. Italian wolves prefer pork to venison
10. KD LUXE Jewelry and Accessories: Introducing Chic Italian Silver and Stainless Collections in Beverly Hills and Hollywood
11. Springer launches new journal with the Italian Association of Nuclear Medicine and Molecular Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 2017 , ... Park Cities Pet Sitter President, Joette White, has been featured ... network. The episode, which was posted this week, features a 30-minute interview of ... Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... financial planning assistance to families and business owners in and around the Hampton ... drive to help prevent all forms of domestic violence. , There are multiple ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics ... of diagnostic information services, today announced that it has ... for 2017 by Fortune. The annual ... companies in the "Health Care: Pharmacy and Other Services" ... diagnostic information services company to attain the designation. This ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
(Date:2/16/2017)... Feb. 16, 2017  Express Scripts (NASDAQ: ESRX ) ... Most Admired Companies within the Health Care: Pharmacy and Other Services ... of the World,s Most Admired Companies," said Tim Wentworth , ... commitment and passion of our 26,000 employees to make medicine more ... ...
Breaking Medicine Technology: